Transparency Market Research

Heparin Market to Earn an Around US $16.3 Bn by the End of 2025

After warfarin, heparin is mostly recommended in the treatment for coagulation disorders and during surgical procedures


Albany, NY -- (SBWIRE) -- 12/08/2017 -- The global heparin market is prognosticated by Transparency Market Research (TMR) to hold a highly consolidated nature where a number of large global companies and a handful of local players could be operating. The report has studied crucial players such as Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Sanofi, Pfizer, Inc., LEO Pharma A/S, Aspen, Baxter International Inc., B. Braun Melsungen AG, and Syntex S.A.

TMR has envisaged the global heparin market to earn an around US$16.3 bn by the end of 2025 while rising at a CAGR of 6.2% during the forecast time frame 2017-2025. In 2017, the market earned an approximately US$10.1 bn. With respect to segmentation by product, low molecular weight heparin (LMWH) could account for a colossal share in the market by the completion of the forecast period. Regionally, North America has been anticipated to secure a lion's share while expanding at a 5.6% CAGR.

Read Report overview @

Anticoagulation Properties Expansively Explored in Treatment of Thromboembolic Disorders

The world heparin market has been prognosticated to rise aggressively in the foreseeable future due to the rising occurrences of thromboembolic disorders. Since years, heparin has been broadly used as an anticoagulant in the treatment and prevention of such disorders. The possible comeback of bovine heparin in the U.S. market by 2022 after reintroduction proposals made by the United States Pharmacopeia (USP) and U.S. Food and Drug Administration (FDA) could raise the hopes of industry players. On the other hand, this could help to address concerns about heparin shortage and adulteration.

After warfarin, heparin is mostly recommended in the treatment for coagulation disorders and during surgical procedures. It is also advisory to administer heparin to patients suffering from transient ischemic attack or stroke and unstable angina. Heparin therapy could be used for such patients owing to the quick onset of anticoagulation activity. Increasing cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) have been prophesied to set the tone for a valuable growth in the market. In the U.K., one in every 1,000 individuals is affected by DVT each year, as per the National Health Service (NHS) data.

Adverse Effects and Possibility of Contamination Promote Disappointed Growth

Primitive forms of heparin such as unfractionated heparin (UFH) could have limited bioavailability and variable anticoagulant effect foretold to affect the acceptance and sales of heparin-based products. Adverse effects such as heparin-induced thrombocytopenia (HIT) and hemorrhage could also discourage the adoption of UFH. However, as compared to LMWH and ultra-low molecular weight heparin (ULMWH), the reversal of heparin overdose associated with UFH could be easily achieved using protamine sulfate.

Request Sample Report@

Poor yield and the risk of contamination associated with ULMWH have been foreseen to negatively impact its growth in the international heparin market. Moreover, the increased cost of ULMWH owing to chemical-based techniques used for synthesizing and processing could dilute its demand. However, this restraint of the ULMWH market has been expected to be countered with the development of two new methods researched at the University of North Carolina via a series of the bio-enzymatic process. The market could be propelled further with possible price containment because of the emergence of the generic editions of Arixtra.

The information presented in this review is based on a TMR report, titled "Heparin Market (Product - Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH), and Ultra-low Molecular Weight Heparin (ULMWH); Source - Bovine and Porcine; Formulation - Oral and Parenteral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017-2025."